These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 10380683)

  • 21. Production of transmembrane and secreted forms of tumor necrosis factor (TNF)-alpha by HIV-1-specific CD4+ cytolytic T lymphocyte clones. Evidence for a TNF-alpha-independent cytolytic mechanism.
    Liu AY; Miskovsky EP; Stanhope PE; Siliciano RF
    J Immunol; 1992 Jun; 148(12):3789-98. PubMed ID: 1351088
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A stochastic model for early HIV-1 population dynamics.
    Tuckwell HC; Le Corfec E
    J Theor Biol; 1998 Dec; 195(4):451-63. PubMed ID: 9837702
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Course of specific T lymphocyte cytotoxicity, plasma and cellular viral loads, and neutralizing antibody titers in 17 recently seroconverted HIV type 1-infected patients.
    Legrand E; Pellegrin I; Neau D; Pellegrin JL; Ragnaud JM; Dupon M; Guillemain B; Fleury HJ
    AIDS Res Hum Retroviruses; 1997 Nov; 13(16):1383-94. PubMed ID: 9359658
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Allogeneic dendritic cell induction of HIV-specific cytotoxic T lymphocyte responses from T cells of HIV type 1-infected and uninfected individuals.
    Dupuis M; Peshwa MV; Benike C; Kundu SK; Engleman EG; Van Schooten WC; Merigan TC
    AIDS Res Hum Retroviruses; 1997 Jan; 13(1):33-9. PubMed ID: 8989425
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The role of the cytotoxic T-lymphocyte response and virus cytopathogenicity in the virus decline during antiviral therapy.
    Ganusov VV
    Proc Biol Sci; 2003 Jul; 270(1523):1513-8. PubMed ID: 12965018
    [TBL] [Abstract][Full Text] [Related]  

  • 26. CD8+ cytolytic T lymphocytes become infected in vitro in the process of killing HIV-1-infected target cells.
    De Maria A; Colombini S; Schnittman SM; Moretta L
    Eur J Immunol; 1994 Mar; 24(3):531-6. PubMed ID: 7907291
    [TBL] [Abstract][Full Text] [Related]  

  • 27. HIV evolution and progression of the infection to AIDS.
    Huang G; Takeuchi Y; Korobeinikov A
    J Theor Biol; 2012 Aug; 307():149-59. PubMed ID: 22634206
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Lymphocyte dynamics, apoptosis and HIV infection.
    Frost SD; Michie CA
    Trends Microbiol; 1996 Feb; 4(2):77-82. PubMed ID: 8820572
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Differential susceptibility of leukocyte subsets to cytotoxic T cell killing: implications for HIV immunopathogenesis.
    Liu J; Roederer M
    Cytometry A; 2007 Feb; 71(2):94-104. PubMed ID: 17200952
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Virus-specific cytotoxic T lymphocyte responses in patients infected with the human immunodeficiency virus, HIV-1.
    Rivière Y
    Cell Mol Biol (Noisy-le-grand); 1994; 40 Suppl 1():45-8. PubMed ID: 7950861
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A delay-differential equation model of HIV infection of CD4(+) T-cells.
    Culshaw RV; Ruan S
    Math Biosci; 2000 May; 165(1):27-39. PubMed ID: 10804258
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Infection dynamics in HIV-specific CD4 T cells: does a CD4 T cell boost benefit the host or the virus?
    Wodarz D; Hamer DH
    Math Biosci; 2007 Sep; 209(1):14-29. PubMed ID: 17379260
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Global stability of HIV infection of CD4+ T cells and macrophages with CTL immune response and distributed delays.
    Elaiw AM; Abukwaik RM; Alzahrani EO
    Comput Math Methods Med; 2013; 2013():653204. PubMed ID: 24363778
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Evolution and plasticity of CTL responses against HIV.
    Autran B; Hadida F; Haas G
    Curr Opin Immunol; 1996 Aug; 8(4):546-53. PubMed ID: 8794018
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cytotoxic T lymphocytes and viral turnover in HIV type 1 infection.
    Klenerman P; Phillips RE; Rinaldo CR; Wahl LM; Ogg G; May RM; McMichael AJ; Nowak MA
    Proc Natl Acad Sci U S A; 1996 Dec; 93(26):15323-8. PubMed ID: 8986810
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Optimal HIV treatment by maximising immune response.
    Culshaw RV; Ruan S; Spiteri RJ
    J Math Biol; 2004 May; 48(5):545-62. PubMed ID: 15133623
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Advances in the immunopathology of HIV infection].
    Alcamí J
    Enferm Infecc Microbiol Clin; 2004 Oct; 22(8):486-96. PubMed ID: 15482691
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Are HIV-specific CTL responses salutary or pathogenic?
    Zinkernagel RM
    Curr Opin Immunol; 1995 Aug; 7(4):462-70. PubMed ID: 7495509
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Why can't cytotoxic T cells handle HIV?
    Bevan MJ; Braciale TJ
    Proc Natl Acad Sci U S A; 1995 Jun; 92(13):5765-7. PubMed ID: 7597026
    [No Abstract]   [Full Text] [Related]  

  • 40. Recognition of Apoptotic Cells by Viruses and Cytolytic Lymphocytes: Target Selection in the Fog of War.
    Schwartz D; Iyengar S
    Viral Immunol; 2020 Apr; 33(3):188-196. PubMed ID: 32286181
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.